01367nas a2200253   4500000000100000008004100001260001300042653002300055653002500078653001100103653001100114653001200125653000900137653002500146100001500171700001800186245007100204856005900275300001100334490000700345050003200352520071500384022001401099       1992                            d  c1992 Dec10aBacterial Vaccines10aCase-Control Studies10aFemale10aHumans10aleprosy10aMale10aMycobacterium leprae1 aBhatki W S1 aChulawala R G00aImmunotherapeutic potential of ICRC vaccine: a case control study.  uhttp://leprev.ilsl.br/pdfs/1992/v63n4/pdf/v63n4a08.pdf  a358-640 v63  aInfolep Library - available3 a<p>A bacteriological follow-up of 16 lepromatous patients with a high initial Bacteriological Index (BI) showed that in 8 randomly selected patients who received single doses of ICRC Vaccine (C44) at the onset of multidrug therapy, the average reduction of BI was from 4.4+ to 1+ in 2 years--3 of these patients became negative and 3 showed BI 1+ or less. Comparable bacteriological assessments in 8 non-vaccinated but otherwise similar patients showed an average reduction of BI from 4.7+ to 2.6+, i.e. consistent with the expected response to MDT in lepromatous patients. Here we discuss the role of immunotherapy and the selection of a desirable antileprosy vaccine in the context of fixed-duration MDT.</p>  a0305-7518